Drug-drug interactions in patients treated for cancer: A prospective study on clinical interventions

Annals of Oncology

Volumn 26, Issue 5, 2015, Pages 992-997

  Van Leeuwen, Roelof W F ^a,d   Jansman, F G A ^b,c   Van den Bemt, P M L A ^a   De Man, F ^a   Piran, F ^a   Vincenten, I ^a   Jager, A ^d   Rijneveld, A W ^d   Brugma, J D ^a   Mathijssen, R H J ^d   Van Gelder, T ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b DEVENTER HOSPITAL   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Cancer; Drug drug interactions; Medication review; Pharmacodynamics; Pharmacokinetics; Pharmacology

Indexed keywords

ALLOPURINOL; ANTINEOPLASTIC AGENT; CORTICOSTEROID; COUMARIN; HERBACEOUS AGENT; MERCAPTOPURINE; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; NON PRESCRIPTION DRUG;

ADULT; AGED; AMBULATORY CARE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SCREENING; CHEMORADIOTHERAPY; COMORBIDITY; COOPERATION; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MYELODYSPLASTIC SYNDROME; NERVOUS SYSTEM TUMOR; ONCOLOGIST; PHARMACIST; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT INDICATION; UROGENITAL TRACT CANCER; COMPUTER PROGRAM; DRUG INTERACTION; HOSPITAL PHARMACY; INTRAVENOUS DRUG ADMINISTRATION; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; NETHERLANDS; ODDS RATIO; ORAL DRUG ADMINISTRATION; POLYPHARMACY; RISK ASSESSMENT; STATISTICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTINEOPLASTIC AGENTS; COMORBIDITY; DRUG INTERACTIONS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; NETHERLANDS; NONPRESCRIPTION DRUGS; ODDS RATIO; PHARMACY SERVICE, HOSPITAL; POLYPHARMACY; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SOFTWARE; YOUNG ADULT;

EID: 84929082748     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv029     Document Type: Article

References (15)

1. Buajordet I, Ebbesen J, Erikssen J et al. Fatal adverse drug events: the paradox of drug treatment. J Intern Med 2001; 250: 327-341.
2. van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol 2014; 15: e315-e326.
3. van Leeuwen RW, Brundel DH, Neef C et al. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer 2013; 108: 1071-1078.
4. van Leeuwen RW, Swart EL, Boven E et al. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol 2011; 22: 2334-2341.
5. Mathijssen RH, Sparreboom A, Verweij J. Determining the optimal dose in the development of anticancer agents. Nat Rev Clin Oncol 2014; 11: 272-281.
6. Riechelmann RP, Tannock IF, Wang L et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007; 99: 592-600.
7. http://www.micromedexsolutions.com (18 March 2014, date last accessed).
8. www.drugs.com (18 March 2014, date last accessed).
9. Lemachatti J, Leveque D, Beretz L, Bergerat JP. Potential pharmacokinetic interactions affecting antitumor drug disposition in cancer patients. Anticancer Res 2009; 29: 4741-4744.
10. Lanza FL, Chan FK, Quigley EM, Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104: 728-738.
11. http://crediblemeds.org (18 March 2014, date last accessed).
12. van der Velde N, Stricker BH, Pols HA, van der Cammen TJ. Risk of falls after withdrawal of fall-risk-increasing drugs: a prospective cohort study. Br J Clin Pharmacol 2007; 63: 232-237.
13. Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm 2004; 61: 380-385.
14. Rommers MK, Teepe-Twiss IM, Guchelaar HJ. Preventing adverse drug events in hospital practice: an overview. Pharmacoepidemiol Drug Saf 2007; 16: 1129-1135.
15. Tascilar M, de Jong FA, Verweij J, Mathijssen RH. Complementary and alternative medicine during cancer treatment: beyond innocence. Oncologist 2006; 11: 732-741.